Castle Biosciences, Inc.
CSTLHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeCastle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal. The $1.00B market capitalization puts CSTL squarely in small-cap range for its industry. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions.
Market Cap
$1.00B
Beta
1.00
P/E (TTM)
—
P/E (Fwd)
-33.13
EPS (TTM)
$-0.64
EPS (Fwd)
$-0.99
ROE
-4.2%
ROA
-1.4%
Cash
$266.8M
Total Debt
$36.6M
Free CF
-$7.3M
52W Change
43.5%
Annual Financials
Cash vs Debt
Where CSTL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CSTL finished 27.65% above its 150-day moving average ($26.18) and 13.56% above its 200-day moving average ($29.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CSTL overbought or oversold?
At the September 3, 2026 close, CSTL's RSI(14) was 61.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $266.8M in cash comfortably exceeding the $36.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$7.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -4.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $137.0M (2022) to $344.2M (2025), reflecting a 151% increase over the period.
With cash comfortably exceeding debt, CSTL has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CSTL.